February 22, 2017 / 12:49 PM / 6 months ago

BRIEF-Esperion posts Q4 loss per share $1.29

Feb 22 (Reuters) - Esperion Therapeutics Inc

* Esperion provides bempedoic acid development program update; reports fourth quarter and full year 2016 financial results

* Esperion Therapeutics Inc - expects full-year 2017 net cash used in operating activities to be approximately $125 to $135 million

* Esperion Therapeutics Inc says estimates that current cash resources are sufficient to fund operations into early 2019

* Qtrly loss per share $1.29

* Esperion Therapeutics Inc - company estimates that current cash resources are sufficient to fund operations into early 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below